SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Arpit Mehrotra, Rajat Sandhir, Mitochondrial cofactors in experimental Huntington's disease: Behavioral, biochemical and histological evaluation, Behavioural Brain Research, 2014, 261, 345

    CrossRef

  2. 2
    Florian Haun, Tomohiro Nakamura, Alicia D. Shiu, Dong-Hyung Cho, Taiji Tsunemi, Emily A. Holland, Albert R. La Spada, Stuart A. Lipton, S-Nitrosylation of Dynamin-Related Protein 1 Mediates Mutant Huntingtin-Induced Mitochondrial Fragmentation and Neuronal Injury in Huntington's Disease, Antioxidants & Redox Signaling, 2013, 19, 11, 1173

    CrossRef

  3. 3
    Matthew K. Brittain, Tatiana Brustovetsky, Patrick L. Sheets, Joel M. Brittain, Rajesh Khanna, Theodore R. Cummins, Nickolay Brustovetsky, Delayed calcium dysregulation in neurons requires both the NMDA receptor and the reverse Na+/Ca2+ exchanger, Neurobiology of Disease, 2012, 46, 1, 109

    CrossRef

  4. 4
    Michelle E. Ehrlich, Huntington’s Disease and the Striatal Medium Spiny Neuron: Cell-Autonomous and Non-Cell-Autonomous Mechanisms of Disease, Neurotherapeutics, 2012, 9, 2, 270

    CrossRef

  5. 5
    Mahesh Ramalingam, Sung-Jin Kim, Reactive oxygen/nitrogen species and their functional correlations in neurodegenerative diseases, Journal of Neural Transmission, 2012, 119, 8, 891

    CrossRef

  6. 6
    Veronica Costa, Luca Scorrano, Shaping the role of mitochondria in the pathogenesis of Huntington's disease, The EMBO Journal, 2012, 31, 8
  7. 7
    Herman H. H. B. M. van Haagen, Peter A. C. 't Hoen, Antoine de Morrée, Willeke M. C. van Roon-Mom, Dorien J. M. Peters, Marco Roos, Barend Mons, Gert-Jan van Ommen, Martijn J. Schuemie, In silico discovery and experimental validation of new protein–protein interactions, PROTEOMICS, 2011, 11, 5
  8. 8
    Ming-Chang Chiang, Yijuang Chern, Chiun-Gung Juo, The dysfunction of hepatic transcriptional factors in mice with Huntington's Disease, Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2011, 1812, 9, 1111

    CrossRef

  9. 9
    Jinho Kim, Olivia L. Bordiuk, Robert J. Ferrante, Pathophysiology, Pharmacology, and Biochemistry of Dyskinesia, 2011,

    CrossRef

  10. 10
    Ina Han, YiMei You, Jeffrey H. Kordower, Scott T. Brady, Gerardo A. Morfini, Differential vulnerability of neurons in Huntington’s disease: the role of cell type-specific features, Journal of Neurochemistry, 2010, 113, 5
  11. 11
    Sami Reijonen, Jyrki P. Kukkonen, Alise Hyrskyluoto, Jenny Kivinen, Minna Kairisalo, Nobuyuki Takei, Dan Lindholm, Laura Korhonen, Downregulation of NF-κB signaling by mutant huntingtin proteins induces oxidative stress and cell death, Cellular and Molecular Life Sciences, 2010, 67, 11, 1929

    CrossRef

  12. 12
    Bruno Gualano, Guilherme Giannini Artioli, Jacques R. Poortmans, Antonio Herbert Lancha Junior, Exploring the therapeutic role of creatine supplementation, Amino Acids, 2010, 38, 1, 31

    CrossRef

  13. You have open access to this content13
    Veronica Costa, Marta Giacomello, Roman Hudec, Raffaele Lopreiato, Gennady Ermak, Dmitri Lim, Walter Malorni, Kelvin J. A. Davies, Ernesto Carafoli, Luca Scorrano, Mitochondrial fission and cristae disruption increase the response of cell models of Huntington's disease to apoptotic stimuli, EMBO Molecular Medicine, 2010, 2, 12
  14. 14
    Raquel Duran, Francisco J. Barrero, Blas Morales, Juan D. Luna, Manuel Ramirez, Francisco Vives, Oxidative stress and plasma aminopeptidase activity in Huntington’s disease, Journal of Neural Transmission, 2010, 117, 3, 325

    CrossRef

  15. 15
    Daniel J. Ho, Noel Y. Calingasan, Elizabeth Wille, Magali Dumont, M. Flint Beal, Resveratrol protects against peripheral deficits in a mouse model of Huntington's disease, Experimental Neurology, 2010, 225, 1, 74

    CrossRef

  16. 16
    Susana Rivera-Mancía, Iván Pérez-Neri, Camilo Ríos, Luis Tristán-López, Liliana Rivera-Espinosa, Sergio Montes, The transition metals copper and iron in neurodegenerative diseases, Chemico-Biological Interactions, 2010, 186, 2, 184

    CrossRef

  17. 17
    Enn Seppet, Marju Gruno, Ants Peetsalu, Zemfira Gizatullina, Huu Phuc Nguyen, Stefan Vielhaber, Manfred H.P. Wussling, Sonata Trumbeckaite, Odeta Arandarcikaite, Doreen Jerzembeck, Maria Sonnabend, Katharina Jegorov, Stephan Zierz, Frank Striggow, Frank N. Gellerich, Mitochondria and Energetic Depression in Cell Pathophysiology, International Journal of Molecular Sciences, 2009, 10, 5, 2252

    CrossRef

  18. 18
    Wolfgang Fecke, Marco Gianfriddo, Giovanni Gaviraghi, Georg C. Terstappen, Freddy Heitz, Small molecule drug discovery for Huntington's Disease, Drug Discovery Today, 2009, 14, 9-10, 453

    CrossRef

  19. 19
    Peter O. Bauer, Nobuyuki Nukina, The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies, Journal of Neurochemistry, 2009, 110, 6
  20. 20
    S. Cipriani, E. Bizzoco, M. Gianfriddo, A. Melani, M.G. Vannucchi, F. Pedata, Adenosine A2A receptor antagonism increases nNOS-immunoreactive neurons in the striatum of Huntington transgenic mice, Experimental Neurology, 2008, 213, 1, 163

    CrossRef

  21. 21
    H. Diana Rosas, David H. Salat, Stephanie Y. Lee, Alexandra K. Zaleta, Nathanael Hevelone, Steven M. Hersch, Complexity and Heterogeneity: What Drives the Ever-changing Brain in Huntington's Disease?, Annals of the New York Academy of Sciences, 2008, 1147, 1
  22. 22
    Peter J. Adhihetty, M. Flint Beal, Creatine and Its Potential Therapeutic Value for Targeting Cellular Energy Impairment in Neurodegenerative Diseases, NeuroMolecular Medicine, 2008, 10, 4, 275

    CrossRef

  23. 23
    Edward C. Stack, Wayne R. Matson, Robert J. Ferrante, Evidence of Oxidant Damage in Huntington's Disease: Translational Strategies Using Antioxidants, Annals of the New York Academy of Sciences, 2008, 1147, 1
  24. 24
    Robert H. Andres, Angélique D. Ducray, Uwe Schlattner, Theo Wallimann, Hans Rudolf Widmer, Functions and effects of creatine in the central nervous system, Brain Research Bulletin, 2008, 76, 4, 329

    CrossRef

  25. 25
    Mark P. Mattson, Glutamate and Neurotrophic Factors in Neuronal Plasticity and Disease, Annals of the New York Academy of Sciences, 2008, 1144, 1
  26. 26
    James W. Simpkins, James A. Dykens, Mitochondrial mechanisms of estrogen neuroprotection, Brain Research Reviews, 2008, 57, 2, 421

    CrossRef

  27. 27
    Frédéric Saudou, Sandrine Humbert, Dementias, 2008,

    CrossRef

  28. 28
    Li Zhu, You Jia Xu, Fang Du, Zhong Ming Qian, Ginkgolides protect primary cortical neurons from potassium cyanide-induced hypoxic injury, Experimental Brain Research, 2007, 179, 4, 665

    CrossRef

  29. 29
    Edward C Stack, Robert J Ferrante, Huntington's disease: progress and potential in the field, Expert Opinion on Investigational Drugs, 2007, 16, 12, 1933

    CrossRef

  30. 30
    H. Varma, R. Cheng, C. Voisine, A. C. Hart, B. R. Stockwell, Inhibitors of metabolism rescue cell death in Huntington's disease models, Proceedings of the National Academy of Sciences, 2007, 104, 36, 14525

    CrossRef

  31. 31
    Stephen M. Altmann, Andrey Muryshev, Elisa Fossale, Michele M. Maxwell, Francine N. Norflus, Jonathan Fox, Steven M. Hersch, Anne B. Young, Marcy E. MacDonald, Ruben Abagyan, Aleksey G. Kazantsev, Discovery of Bioactive Small-Molecule Inhibitor of Poly ADP-Ribose Polymerase: Implications for Energy-Deficient Cells, Chemistry & Biology, 2006, 13, 7, 765

    CrossRef

  32. 32
    Patrick Weydt, Victor V. Pineda, Anne E. Torrence, Randell T. Libby, Terrence F. Satterfield, Eduardo R. Lazarowski, Merle L. Gilbert, Gregory J. Morton, Theodor K. Bammler, Andrew D. Strand, Libin Cui, Richard P. Beyer, Courtney N. Easley, Annette C. Smith, Dimitri Krainc, Serge Luquet, Ian R. Sweet, Michael W. Schwartz, Albert R. La Spada, Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1α in Huntington's disease neurodegeneration, Cell Metabolism, 2006, 4, 5, 349

    CrossRef

  33. 33
    Ali Sazci, Emel Ergul, Ismail Kucukali, Ihsan Kara, Guner Kaya, Association of the C677T and A1298C polymorphisms of methylenetetrahydrofolate reductase gene with schizophrenia: Association is significant in men but not in women, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2005, 29, 7, 1113

    CrossRef

  34. 34
    Byoung-Il Bae, Hong Xu, Shuichi Igarashi, Masahiro Fujimuro, Nishant Agrawal, Yoichi Taya, S. Diane Hayward, Timothy H. Moran, Craig Montell, Christopher A. Ross, Solomon H. Snyder, Akira Sawa, p53 Mediates Cellular Dysfunction and Behavioral Abnormalities in Huntington’s Disease, Neuron, 2005, 47, 1, 29

    CrossRef

  35. 35
    Xiaofeng Gu, Chenjian Li, Weizheng Wei, Victor Lo, Shiaoching Gong, Shi-Hua Li, Takuji Iwasato, Shigeyoshi Itohara, Xiao-Jiang Li, Istvan Mody, Nathaniel Heintz, X. William Yang, Pathological Cell-Cell Interactions Elicited by a Neuropathogenic Form of Mutant Huntingtin Contribute to Cortical Pathogenesis in HD Mice, Neuron, 2005, 46, 3, 433

    CrossRef

  36. 36
    Gerardo Morfini, Gustavo Pigino, Scott T. Brady, Polyglutamine expansion diseases: failing to deliver, Trends in Molecular Medicine, 2005, 11, 2, 64

    CrossRef

  37. 37
    Hoon Ryu, H. Diana Rosas, Steven M. Hersch, Robert J. Ferrante, The therapeutic role of creatine in Huntington's disease, Pharmacology & Therapeutics, 2005, 108, 2, 193

    CrossRef

  38. 38
    Paula Dietrich, Ioannis Dragatsis, Animal Models of Movement Disorders, 2005,

    CrossRef

  39. 39
    Deepa S. Maharaj, Roderick B. Walker, Beverley D. Glass, Santy Daya, 6-Hydroxymelatonin protects against cyanide induced oxidative stress in rat brain homogenates, Journal of Chemical Neuroanatomy, 2003, 26, 2, 103

    CrossRef

  40. 40
    Mark P Mattson, Thomas B Shea, Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders, Trends in Neurosciences, 2003, 26, 3, 137

    CrossRef

  41. 41
    Alexander V Panov, James R Burke, Warren J Strittmatter, J.Timothy Greenamyre, In vitro effects of polyglutamine tracts on Ca2+-dependent depolarization of rat and human mitochondria: relevance to Huntington’s disease, Archives of Biochemistry and Biophysics, 2003, 410, 1, 1

    CrossRef

  42. 42
    Mark P. Mattson, Wenzhen Duan, Zhihong Guo, Meal size and frequency affect neuronal plasticity and vulnerability to disease: cellular and molecular mechanisms, Journal of Neurochemistry, 2003, 84, 3
  43. 43
    Sung-Jo Kim, Tae-soo Kim, Sunghoi Hong, Hyangshuk Rhim, Ick Young Kim, Seongman Kang, Oxidative stimuli affect polyglutamine aggregation and cell death in human mutant ataxin-1-expressing cells, Neuroscience Letters, 2003, 348, 1, 21

    CrossRef

  44. 44
    Joan S Steffan, Leslie Michels Thompson, Targeting aggregation in the development of therapeutics for the treatment of Huntington’s disease and other polyglutamine repeat diseases, Expert Opinion on Therapeutic Targets, 2003, 7, 2, 201

    CrossRef

  45. 45
    Arthur J.L. Cooper, Thomas M. Jeitner, Vittorio Gentile, John P. Blass, Cross linking of polyglutamine domains catalyzed by tissue transglutaminase is greatly favored with pathological-length repeats: does transglutaminase activity play a role in (CAG)n/Qn-expansion diseases?, Neurochemistry International, 2002, 40, 1, 53

    CrossRef

  46. 46
    BARRY HALLIWELL, Hypothesis: Proteasomal Dysfunction, Annals of the New York Academy of Sciences, 2002, 962, 1
  47. 47
    Christopher A Ross, Russell L Margolis, Huntington's disease, Clinical Neuroscience Research, 2001, 1, 1-2, 142

    CrossRef

  48. You have free access to this content48
    A. Wallace Deckel, Nitric oxide and nitric oxide synthase in Huntington's disease, Journal of Neuroscience Research, 2001, 64, 2